[New possibilities of prevention of occupational Candida albicans infection] NLM AIDSLINE Important note: Information in this article was accurate in 1990. The state of the art may have changed since the publication date.

Click here to return to AIDSLINE main menu
DonateNow
Print this Article


[New possibilities of prevention of occupational Candida albicans infection]

Przegl Dermatol. 1988 Nov-Dec;75(6):425-30. Unique Identifier : AIDSLINE MED/90047753
Maleszka R; Maleszka A

Abstract: The effects were studied in vitro of a score of various additives to toilet soaps on strains of Candida albicans isolated from patients. Their effect on the basic properties of toilet soaps was studied, determining foam production and the index of foam stability, and their resistance to high temperature was determined since in the process of production high temperature might reduce their effects on C. albicans. The strongest fungicidal effect was exerted in strongly alkaline soap solutions by Clotrimazole. Good effects were obtained also using Clioquinol, a derivative of 8-hydroxyquinoline. The results of these studies suggest that certain substances may be added for exerting a fungicidal effect in alkaline medium protecting thus against fungal infections.
Keywords: Antifungal Agents/ADMINISTRATION & DOSAGE/*PHARMACOLOGY Candida albicans/*DRUG EFFECTS/PATHOGENICITY Candidiasis, Cutaneous/*PREVENTION & CONTROL Comparative Study Dermatitis, Occupational/*PREVENTION & CONTROL Dose-Response Relationship, Drug English Abstract *Handwashing Human In Vitro Pharmaceutic Aids/ADMINISTRATION & DOSAGE/PHARMACOLOGY Soaps/*PHARMACOLOGY Surface-Active Agents/*PHARMACOLOGY JOURNAL ARTICLEKWDantifungalagents/administration&dosage/KWDpharmacologycandidaalbicans/KWDdrugeffects/pathogenicitycandidiasis,cutaneous/KWDprevention&controlcomparativestudydermatitis,occupational/KWDprevention&controldose-responserelationship,drugenglishabstractKWDhandwashinghumaninvitropharmaceuticaids/administration&dosage/pharmacologysoaps/KWDpharmacologysurface-activeagents/KWDpharmacologyjournalarticle
900228
M9020552

Copyright © 1990 - National Library of Medicine. Reproduced under license with the National Library of Medicine, Bethesda, MD.

AEGiS is a 501(c)3, not-for-profit, tax-exempt, educational corporation. AEGiS is made possible through unrestricted funding from Boehringer Ingelheim, Bridgestone/Firestone Charitable Trust, Bristol-Myers Squibb Company, Elton John AIDS Foundation, Gill Foundation, the National Library of Medicine, Quest Diagnostics, Roche and Trimeris, and donations from users like you. Always watch for outdated information. This article first appeared in 1990. This material is designed to support, not replace, the relationship that exists between you and your doctor.

AEGiS presents published material, reprinted with permission and neither endorses nor opposes any material. All information contained on this website, including information relating to health conditions, products, and treatments, is for informational purposes only. It is often presented in summary or aggregate form. It is not meant to be a substitute for the advice provided by your own physician or other medical professionals. Always discuss treatment options with a doctor who specializes in treating HIV.

Copyright ©1980, 1990. AEGiS. All materials appearing on AEGiS are protected by copyright as a collective work or compilation under U.S. copyright and other laws and are the property of AEGiS, or the party credited as the provider of the content. .